Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNASDAQ:DYNNASDAQ:EWTXNASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.43-0.5%$13.89$7.64▼$17.75$1.60B1.762.26 million shs2.23 million shsDYNDyne Therapeutics$14.41-0.3%$11.19$6.36▼$47.45$1.64B1.171.69 million shs1.75 million shsEWTXEdgewise Therapeutics$15.29-0.8%$14.42$10.60▼$38.12$1.61B0.281.21 million shs979,905 shsSIGASIGA Technologies$6.36-1.2%$5.98$4.95▼$12.83$454.37M0.93732,446 shs502,961 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%-6.54%-1.47%-8.14%+65.80%DYNDyne Therapeutics0.00%-1.97%+22.74%+19.59%-56.35%EWTXEdgewise Therapeutics0.00%+0.33%+5.81%-40.44%-14.49%SIGASIGA Technologies0.00%+5.47%+7.43%+13.98%-19.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics1.8792 of 5 stars3.41.00.00.02.11.70.6DYNDyne Therapeutics2.4414 of 5 stars4.50.00.00.02.22.50.0EWTXEdgewise Therapeutics2.6529 of 5 stars4.41.00.00.01.53.30.0SIGASIGA Technologies2.4389 of 5 stars0.03.00.00.02.70.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8039.99% UpsideDYNDyne Therapeutics 3.00Buy$44.93211.79% UpsideEWTXEdgewise Therapeutics 2.78Moderate Buy$39.78160.16% UpsideSIGASIGA Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SIGA, ARQT, DYN, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025DYNDyne TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/5/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$48.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$212.82M7.52N/AN/A$0.94 per share14.29DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/ASIGASIGA Technologies$120.33M3.78$1.00 per share6.34$2.77 per share2.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%8/13/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)EWTXEdgewise Therapeutics-$100.16M-$1.55N/AN/AN/AN/A-26.83%-25.67%8/6/2025 (Estimated)SIGASIGA Technologies$68.07M$0.675.305.09N/A49.33%49.06%38.72%7/30/2025 (Estimated)Latest SIGA, ARQT, DYN, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45-$0.43+$0.02-$0.43N/AN/A5/8/2025Q1 2025SIGASIGA TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 million5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ALatest SIGA, ARQT, DYN, and EWTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASIGA Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.672.462.38DYNDyne TherapeuticsN/A17.0217.02EWTXEdgewise TherapeuticsN/A26.3526.35SIGASIGA TechnologiesN/A8.105.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ADYNDyne Therapeutics96.68%EWTXEdgewise TherapeuticsN/ASIGASIGA Technologies55.40%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%DYNDyne Therapeutics14.14%EWTXEdgewise Therapeutics23.20%SIGASIGA Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableEWTXEdgewise Therapeutics60105.20 million71.86 millionOptionableSIGASIGA Technologies4071.44 million70.31 millionOptionableSIGA, ARQT, DYN, and EWTX HeadlinesRecent News About These CompaniesWhy Siga Technologies Inc. (SIGA) Dipped More Than Broader Market TodayJune 13 at 6:46 PM | zacks.comSIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Harbor Capital Advisors Inc.June 13 at 4:11 AM | marketbeat.comInvestors Purchase Large Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)June 12 at 3:45 AM | americanbankingnews.comTraders Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)June 12 at 2:50 AM | marketbeat.comSIGA Technologies, Inc. (NASDAQ:SIGA) Short Interest Down 12.5% in MayJune 4, 2025 | marketbeat.comTraders Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)May 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 87,853 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)May 21, 2025 | marketbeat.comStock Traders Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)May 17, 2025 | marketbeat.comWe Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster EarningsMay 16, 2025 | finance.yahoo.comUndiscovered Gems in the US Market for May 2025May 16, 2025 | finance.yahoo.comSIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)May 10, 2025 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSIGA Reports Financial Results for Three Months Ended March 31, 2025May 8, 2025 | globenewswire.comCalculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)May 2, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for InvestorsMay 1, 2025 | zacks.comSIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 ResultsMay 1, 2025 | globenewswire.comChiliz joins SIGA to help drive integrity in sportApril 30, 2025 | en.as.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%April 29, 2025 | aaii.comHere's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market TodayApril 25, 2025 | zacks.comSiga Technologies Inc. (SIGA) Outperforms Broader Market: What You Need to KnowApril 23, 2025 | zacks.comSiga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should KnowApril 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsJoby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBy Jeffrey Neal Johnson | June 4, 2025View Joby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsSteel Dynamics Shares Climb After Tariff AnnouncementBy Dan Schmidt | June 3, 2025View Steel Dynamics Shares Climb After Tariff AnnouncementSIGA, ARQT, DYN, and EWTX Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.43 -0.07 (-0.52%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$13.46 +0.04 (+0.26%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Dyne Therapeutics NASDAQ:DYN$14.41 -0.05 (-0.35%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$14.40 -0.01 (-0.03%) As of 06/13/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Edgewise Therapeutics NASDAQ:EWTX$15.29 -0.13 (-0.84%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$15.64 +0.35 (+2.29%) As of 06/13/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.SIGA Technologies NASDAQ:SIGA$6.36 -0.08 (-1.24%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.36 0.00 (-0.08%) As of 06/13/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
